Lipoprotein disorders classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(42 intermediate revisions by 12 users not shown)
Line 1: Line 1:
'''For patient information click [[Hyperlipidemia (patient information)|here]]'''
__NOTOC__
{{CMG}}; {{AE}}
{{Hyperlipidemia}}


{{CMG}}
==Overview==
Lipoprotein disorders can be classified according to the [[Donald S. Fredrickson|Fredrickson]] classification which is based on the pattern of lipoproteins on [[electrophoresis]] or [[Ultracentrifuge|ultracentrifugation]].<ref>Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. ''Circulation'' 1965;31:321-7. PMID 14262568.</ref> It was later adopted by the [[World Health Organization]] (WHO). It does not directly account for [[High density lipoprotein|HDL]], and it does not distinguish among the different [[genes]] that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered outdated by many.


{{DiseaseDisorder infobox |
==Classification==
  Name        = Hyperlipidemia |
There are several ways in which lipoprotein abnormalities are classified. Lipoprotein disorders can be classified according to:
  ICD10      = {{ICD10|E|78||e|78}} |
  ICD9        = {{ICD9|272.0}}-{{ICD9|272.4}} |
  DiseasesDB  = 6255|
}}
{{SI}}


==Overview==
* The pattern of change in the lipoprotein levels, described as hyperlipidemia (increase in lipid levels) and hypolipidemia (decrease in lipid levels):  However, this classification is problematic because the lipids and lipoproteins levels in some situation can be elevated in some types of lipoproteins and lipids and decreased in others.
 
* [[Phenotype]], or the specific type of lipid that is increased, as classified by Fredrickson: This classification is problematic because it does not include abnormalities in the level of HDL.
 
* [[Etiology]], as primary (genetic) or secondary to another condition: This classification can be problematic, because most conditions involve the intersection of genetics and lifestyle issues. However, there are a few well defined genetic conditions that are usually easy to identify.
 
* Levels of measured lipids (cholesterol and triglycerides), described as hypercholesterolemia and hypocholesterolemia or hypertriglyceridimia and hypotriglyceridemia: This distinction is not specific because it does not reflect the specific lipoprotein(s) that are abnormally high or low.


Hyperlipidemias are classified according to the '''[[Donald S. Fredrickson|Fredrickson]] classification''' which is based on the pattern of lipoproteins on [[electrophoresis]] or [[Ultracentrifuge|ultracentrifugation]].<ref>Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. ''Circulation'' 1965;31:321-7. PMID 14262568.</ref> It was later adopted by the [[World Health Organization]] (WHO). It does not directly account for [[High density lipoprotein|HDL]], and it does not distinguish among the different [[genes]] that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered dated by many.
===Fredrickson Classification of Hyperlipoproteinemia===
{{familytree/start |summary=Hyperlipoproteinemia}}
{{familytree | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | A01= '''Hyperlipoproteinemia/Hyperlipidemia'''}}
{{familytree | | | | | |,|-|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | | }}
{{familytree | | | | | D01 | | | D02 | | D03 | | D04 | | D05 | | D01= '''Type I:'''<br> [[Familial hyperchylomicronemia]]| D02= '''Type II'''| D03= '''Type III:'''<br>[[Dysbetalipoproteinemia]]| D04= '''Type IV:'''<br>[[Primary hypertriglyceridemia]]<br>| D05= '''Type V:''' <br>[[Mixed hyperlipoproteinemia]]}}
{{familytree | | | | | |!| | |,|-|^|-|.| | |}}
{{familytree | | | | | |!| | E01 | | E02 | | E01= '''Type A:'''<br> [[Familial hypercholesterolemia]]| E02= '''Type B:'''<br> [[Familial combined hyperlipidemia]]}}
{{familytree/end}}


==[[Hyperlipidemia classification | Classification]]==


{| border="1" cellpadding="5" cellspacing="0" align="center" class="sortable"
{| border="1" cellpadding="5" cellspacing="0" align="center" class="sortable"
Line 27: Line 37:
|-
|-
   ! Type I
   ! Type I
   | ''Buerger-Gruetz syndrome'', ''Primary hyperlipoproteinaemia'', or ''Familial hyperchylomicronemia''
   | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or [[familial hyperchylomicronemia]]
   | Decreased [[lipoprotein lipase]] (LPL) or altered [[apolipoprotein C2|ApoC2]]
   | Decreased [[lipoprotein lipase]] (LPL) or altered [[apolipoprotein C2|ApoC2]]
   | Elevated [[Chylomicrons]]
   | Elevated [[chylomicrons]]
   | Diet Control
   | Diet control
|-
|-
   ! Type IIa
   ! Type IIa
   | ''Polygenic hypercholesterolaemia'' or [[Familial hypercholesterolemia]]
   | Polygenic hypercholesterolaemia or familial hypercholesterolemia
   | [[LDL receptor]] deficiency
   | [[LDL receptor]] deficiency
   | Elevated [[LDL]] only
   | Elevated [[LDL]] only
   | Bile Acid Sequestrants, [[Statin]]s, [[Niacin]]
   | Bile acid sequestrants, [[statin]]s, [[niacin]]
|-
|-
   ! Type IIb
   ! Type IIb
   | [[Combined hyperlipidemia]]
   | [[Combined hyperlipidemia]]
   | Decreased [[LDL receptor]] and Increased [[apolipoprotein B|ApoB]]
   | Decreased [[LDL receptor]] and increased [[apolipoprotein B|ApoB]]
   | Elevated [[LDL]] and [[VLDL]] and Triglycerides
   | Elevated [[LDL]], [[VLDL]] and triglycerides
   | [[Statin]]s, [[Niacin]], [[Gemfibrozil]]
   | [[Statin]]s, [[niacin]], [[gemfibrozil]]
|-
|-
   ! Type III
   ! Type III
   | ''Familial Dysbetalipoproteinemia''
   | Familial Dysbetalipoproteinemia
   | Defect in [[apolipoprotein E|ApoE]] synthesis
   | Defect in [[apolipoprotein E|ApoE]] synthesis
   | Increased [[IDL]]
   | Increased [[IDL]]
Line 51: Line 61:
|-
|-
   ! Type IV
   ! Type IV
   | ''Endogenous Hyperlipemia''
   | Endogenous Hyperlipemia
   | Increased [[VLDL]] production and Decreased elimination
   | Increased [[VLDL]] production and decreased elimination
   | Increased [[VLDL]]
   | Increased [[VLDL]]
   | Drug of choice: [[Niacin]]
   | Drug of choice: [[Niacin]]
|-
|-
   ! Type V
   ! Type V
   | ''Familial Hypertriglyceridemia''
   | Familial Hypertriglyceridemia
   | Increased [[VLDL]] production and Decreased [[LPL]]
   | Increased [[VLDL]] production and decreased [[LPL]]
   | Increased [[VLDL]] and [[Chylomicrons]]
   | Increased [[VLDL]] and [[chylomicrons]]
   | [[Niacin]], [[Gemfibrozil]]
   | [[Niacin]], [[gemfibrozil]]
|}
|}


===Hyperlipoproteinemia type I===
====Unclassified forms====
This very rare form (also known as ''Buerger-Gruetz syndrome'', ''primary hyperlipoproteinaemia'', or ''familial hyperchylomicronemia'') is due to a deficiency of [[lipoprotein lipase]] (LPL) or altered [[apolipoprotein C2]], resulting in elevated [[chylomicron]]s, the particles that transfer fatty acids from the [[digestive tract]] to the [[liver]]. Lipoprotein lipase is also responsible for the initial breakdown of endogenously made triacylglycerides in the form of very low density lipoprotein (VLDL). As such, one would expect a defect in LPL to also result in elevated VLDL. Its prevalence is 0.1% of the population.
 
===Hyperlipoproteinemia type II===
Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol.
 
====Type IIa====
{{main|Familial hypercholesterolemia}}
 
This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the [[LDL receptor]] gene on [[chromosome 19]] (0.2% of the population) or the [[apolipoprotein B|ApoB]] gene (0.2%). The familial form is characterized by [[Xanthoma|tendon xanthoma]], [[xanthelasma]] and premature cardiovascular disease.
 
====Type IIb====
The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.
* Familial combined hyperlipoproteinemia (FCH)
* Secondary combined hyperlipoproteinemia (usually in the context of [[metabolic syndrome]], for which it is a diagnostic criterion)
 
====Treatment====
While dietary modification is the initial approach, many patients require treatment with [[statin]]s (HMG-CoA reductase inhibitors) to reduce cardiovascular risk. If the triglyceride level is markedly raised, [[fibrate]]s may be preferable due to their beneficial effects. Combination treatment of statins and fibrates, while highly effective, causes a markedly increased risk of [[myopathy]] and [[rhabdomyolysis]] and is therefore only done under close supervision. Other agents commonly added to statins are [[ezetimibe]], [[niacin]] and [[bile acid sequestrant]]s. There is some evidence for benefit of plant sterol-containing products and [[omega-3 fatty acid|ω<sub>3</sub>-fatty acids]]<ref>Thompson GR. Management of dyslipidaemia. ''Heart'' 2004;90:949-55. PMID 15253984.</ref>
 
===Hyperlipoproteinemia type III===
This form is due to high [[chylomicron]]s and IDL (intermediate density lipoprotein). Also known as ''broad beta disease'' or ''dysbetalipoproteinemia'', the most common cause for this form is the presence of [[Apolipoprotein E|ApoE]] E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Prevalence is 0.02% of the population.
 
===Hyperlipoproteinemia type IV===
This form is due to high [[triglyceride]]s. It is also known as ''[[hypertriglyceridemia]]'' (or ''pure hypertriglyceridemia''). According to the NCEP-ATPIII definition of high triglycerides (>200 mg/dl),
prevalence is about 16% of adult population.<ref>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.  ''Circulation'' 2002; 106; page 3240</ref>
 
===Hyperlipoproteinemia type V===
This type is very similar to type I, but with high [[VLDL]] in addition to chylomicrons.
 
It is also associated with glucose intolerance and hyperuricemia
 
==Unclassified forms==
Non-classified forms are extremely rare:
Non-classified forms are extremely rare:
* Hypo-alpha lipoproteinemia
* Hypo-alpha lipoproteinemia
* Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)
* Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)


==References==
===Classification According to Etiology===
{{reflist}}
{{familytree/start |summary=Lipoprotein/Lipid disorders}}
{{familytree | | | | | | | | | | | A01 | | | | | | | | A01= '''Lipoprotein/Lipid disorders'''}}
{{familytree | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|.| | | }}
{{familytree | | | | | B01 | | | | | | | | | | | | | | B02 | B01= '''Primary'''<br>(Genetic)| B02= '''Secondary'''}}
{{familytree | |,|-|-|-|+|-|-|-|v|-|-|-|-|-|-|-|.| | | |!| | | | }}
{{familytree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | C01= '''LDL'''| C02= '''Chylomicron Remnants'''| C03= '''Lipoproteins Rich in Triglyceride'''<br> '''(Chylomicrons, VLDL, IDL)'''| C04= '''HDL'''| C05='''Multiple lipoproteins'''| C06= [[Alcohol]] <br> [[Diabetes]] <br> [[Drug]]s <br> [[Liver disease]] <br> [[Obesity]] <br> [[Renal disease]] <br> [[Smoking]] <br> [[Thyroid]]}}
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | }}
{{familytree | D01 | | D02 | | D03 | | D04 | | D05 |  D01= '''High LDL:''' <br> -Familial hypercholesterolemia <br> -Familial defective apo B 100 <br> -Autosomal dominant hypercholesterolemia (PCSK9) <br> -Autosomal recessive hypercholesterolemia <br> -Familial sistosterolemia <br> -Familial lipoprotein a lipoproteinemia <br><br> '''Low LDL:''' <br> -Abetalipoproteinemia <br> -Hypobetalipoproteinemia <br> -PCSK 9 deficiency| D02= -Deficiency in hepatic lipase<br> -Type III dysbetalipoproteinemia| D03= -Deficiency in lipoprotein lipase<br> -Deficiency in Apo C-II <br> -Deficiency in Apo A-V <br> -Familial combined hyperlipidemia<br> -Familial hypertriglyceridemia<br> - [[Chylomicron retention disease]]| D04= '''High LDL''':<br> -Cholesteryl ester transferase protein deficiency <br><br>'''Low HDL:''' <br> -Deficiency in Apo A-I<br> -Deficiency in lecithin cholesterol acyltransferase (LCAT) <br>-Familial hypoalphalipoproteinemia<br> -Nieman-Pick disease<br> -Tangier disease| D05=- Familial combined hypolipidemia (ANGPTL3)}}
{{familytree/end}}
 
===Classification According to Laboratory Results===
{{familytree/start |summary= Lipid Laboratory Tests}}
{{familytree | | | | | | | | | | | | | | | A01 | | | |  A01= '''Lipid Laboratory Tests'''}}
{{familytree | | | |,|-|-|-|-|-|-|-|v|-|-|-|^|-|-|-|v|-|-|-|-|-|-|-|.| }}
{{familytree | | | B01 | | | | | | B02 | | | | | | B03 | | | | | | B04 | | | B01= '''[[Cholesterol|Total cholesterol]]'''| B02= '''[[LDL|LDL-C]]'''| B03= '''[[HDL|HDL-C]]'''| B04='''[[Triglyceride]]s'''}}
{{familytree | |,|-|^|-|.| | | |,|-|^|-|.| | | |,|-|^|-|.| | | |,|-|^|-|.| | }}
{{familytree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | C07 | | C08 | C01= [[High cholesterol|High total cholesterol]]| C02=[[Low cholesterol|Low total cholesterol]] | C03= [[High LDL]]| C04= [[Low LDL]]| C05= [[High HDL]]| C06= [[Low HDL]]| C07= [[High triglyceride]]| C08= [[Low triglyceride]]}}
{{familytree/end}}


==External links==
==External links==
* [http://profiles.nlm.nih.gov/FF/Views/Exhibit/visuals/scientist.html The Fredrickson papers (with photos from early lipoprotein research)]
* [http://profiles.nlm.nih.gov/FF/Views/Exhibit/visuals/scientist.html The Fredrickson papers (with photos from early lipoprotein research)]
* {{GPnotebook|745209914}}
<!-- previously these good links (OMIM normally inserted into the Template:Infobox Disease, but here there are separate ones for each Type. Rearranged into a table to try and compact down. -->
{| border=1 cellpadding=6 style="text-align:left"
|-
  ! Hyperlipoproteinemia
  ! OMIM
  ! GPnotebook
  ! WebMD
  ! Others
|-
  ! Type I
  | {{OMIM|238600}}
  | {{GPnotebook|-1389035478}}
  | .
  | [http://www.meritcare.com/hwdb/showTopic.asp?pd_hwid=nord474 MeritCare]
|-
  ! Type IIa
  | rowspan=2 | {{OMIM|144400}}
  | {{GPnotebook|-1664090094}}
  | .
  | rowspan=2 | [http://www.merck.com/mrkshared/mmanual/section2/chapter15/15c.jsp Merck]
|-
  ! Type IIb
  <!-- OMIM for TypeII
-->| {{GPnotebook|-1375338454}}
  | .
  <!-- OMIM for TypeII
-->|-
  ! Type III
  | .
  | {{GPnotebook|630849560}}
  | [http://www.webmd.com/hw/health_guide_atoz/nord163.asp WebMD]
  | [http://health.yahoo.com/ency/healthwise/nord163 Yahoo]
|-
  ! Type IV
  | {{OMIM|144600}}
  | {{GPnotebook|-1362100182}}
  | [http://aolsvc.health.webmd.aol.com/hw/cholesterol_management/nord624.asp WebMD]
  | [http://health.yahoo.com/ency/healthwise/nord624 Yahoo]
|-
  ! Type V
  | {{OMIM|144600}}
  | {{GPnotebook|-1355481046}}
  | .
  | .
|}


{{Metabolic pathology}}
==References==
 
{{reflist|2}}
[[Category:Cardiology]]
[[Category:Lipid disorders]]
[[Category:Mature chapter]]
[[Category:Genetic disorders]]
[[Category:Metabolic disorders]]
 
[[de:Hyperlipoproteinämie]]
[[he:היפרליפידמיה]]
[[pt:Dislipidemia]]
[[ru:Гиперлипидемия]]
[[sv:Hyperlipidemi]]


{{Lipopedia}}
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Lipopedia]]
[[Category:Cardiology]]
[[Category:Endocrinology]]

Latest revision as of 22:30, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Lipoprotein Disorders Microchapters

Patient Information

Overview

Causes

Classification

Hyperlipoproteinemia
Hypolipoproteinemia

Treatment

Overview

Lipoprotein disorders can be classified according to the Fredrickson classification which is based on the pattern of lipoproteins on electrophoresis or ultracentrifugation.[1] It was later adopted by the World Health Organization (WHO). It does not directly account for HDL, and it does not distinguish among the different genes that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered outdated by many.

Classification

There are several ways in which lipoprotein abnormalities are classified. Lipoprotein disorders can be classified according to:

  • The pattern of change in the lipoprotein levels, described as hyperlipidemia (increase in lipid levels) and hypolipidemia (decrease in lipid levels): However, this classification is problematic because the lipids and lipoproteins levels in some situation can be elevated in some types of lipoproteins and lipids and decreased in others.
  • Phenotype, or the specific type of lipid that is increased, as classified by Fredrickson: This classification is problematic because it does not include abnormalities in the level of HDL.
  • Etiology, as primary (genetic) or secondary to another condition: This classification can be problematic, because most conditions involve the intersection of genetics and lifestyle issues. However, there are a few well defined genetic conditions that are usually easy to identify.
  • Levels of measured lipids (cholesterol and triglycerides), described as hypercholesterolemia and hypocholesterolemia or hypertriglyceridimia and hypotriglyceridemia: This distinction is not specific because it does not reflect the specific lipoprotein(s) that are abnormally high or low.

Fredrickson Classification of Hyperlipoproteinemia

 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperlipoproteinemia/Hyperlipidemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type I:
Familial hyperchylomicronemia
 
 
Type II
 
Type III:
Dysbetalipoproteinemia
 
Type IV:
Primary hypertriglyceridemia
 
Type V:
Mixed hyperlipoproteinemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type A:
Familial hypercholesterolemia
 
Type B:
Familial combined hyperlipidemia
 


Fredrickson classification of Hyperlipidemias
Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated chylomicrons Diet control
Type IIa Polygenic hypercholesterolaemia or familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile acid sequestrants, statins, niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and increased ApoB Elevated LDL, VLDL and triglycerides Statins, niacin, gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and decreased LPL Increased VLDL and chylomicrons Niacin, gemfibrozil

Unclassified forms

Non-classified forms are extremely rare:

  • Hypo-alpha lipoproteinemia
  • Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)

Classification According to Etiology

 
 
 
 
 
 
 
 
 
 
Lipoprotein/Lipid disorders
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary
(Genetic)
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL
 
Chylomicron Remnants
 
Lipoproteins Rich in Triglyceride
(Chylomicrons, VLDL, IDL)
 
HDL
 
Multiple lipoproteins
 
Alcohol
Diabetes
Drugs
Liver disease
Obesity
Renal disease
Smoking
Thyroid
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High LDL:
-Familial hypercholesterolemia
-Familial defective apo B 100
-Autosomal dominant hypercholesterolemia (PCSK9)
-Autosomal recessive hypercholesterolemia
-Familial sistosterolemia
-Familial lipoprotein a lipoproteinemia

Low LDL:
-Abetalipoproteinemia
-Hypobetalipoproteinemia
-PCSK 9 deficiency
 
-Deficiency in hepatic lipase
-Type III dysbetalipoproteinemia
 
-Deficiency in lipoprotein lipase
-Deficiency in Apo C-II
-Deficiency in Apo A-V
-Familial combined hyperlipidemia
-Familial hypertriglyceridemia
- Chylomicron retention disease
 
High LDL:
-Cholesteryl ester transferase protein deficiency

Low HDL:
-Deficiency in Apo A-I
-Deficiency in lecithin cholesterol acyltransferase (LCAT)
-Familial hypoalphalipoproteinemia
-Nieman-Pick disease
-Tangier disease
 
- Familial combined hypolipidemia (ANGPTL3)

Classification According to Laboratory Results

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lipid Laboratory Tests
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total cholesterol
 
 
 
 
 
LDL-C
 
 
 
 
 
HDL-C
 
 
 
 
 
Triglycerides
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High total cholesterol
 
Low total cholesterol
 
High LDL
 
Low LDL
 
High HDL
 
Low HDL
 
High triglyceride
 
Low triglyceride

External links

References

  1. Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. Circulation 1965;31:321-7. PMID 14262568.

Template:WikiDoc Sources